1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Poziotinib’s Shift Of Focus To HER2 May Increase Approval Chances

Potential First-Line Therapy

 
• By Jung Won Shin

Encouraging new data for Spectrum/Hanmi’s poziotinib presented at ESMO may increase the chances of approval for the pan-HER inhibitor as a possible first-line therapy for NSCLC with the HER2 exon 20 insertion mutation, although the patient population is limited.

positive
No Specific Approved NSCLS Therapy So Far For HER2 Exon 20 Insertion Mutation • Source: Alamy

Spectrum Pharmaceuticals Inc. presented positive data from Cohort 4 of the Phase II ZENITH20 study with poziotinib in the first-line setting in non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations at the recent European Society for Medical Oncology (ESMO) Congress, showing the drug's potential in an area with high unmet need and few available treatment options.

Poziotinib, licensed in from South Korea’s Hanmi Pharmaceutical Co., Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D